UBS Group reaffirmed their sell rating on shares of AstraZeneca (LON:AZN) in a research note released on Tuesday morning, ThisIsMoney.Co.Uk reports.
Other research analysts also recently issued research reports about the stock. Barclays boosted their price target on shares of AstraZeneca from GBX 6,800 ($88.85) to GBX 7,000 ($91.47) and gave the stock an overweight rating in a research report on Monday, April 1st. Goldman Sachs Group set a GBX 5,000 ($65.33) price target on shares of AstraZeneca and gave the stock a sell rating in a research report on Wednesday, April 3rd. Liberum Capital boosted their price target on shares of AstraZeneca from GBX 5,800 ($75.79) to GBX 6,400 ($83.63) and gave the stock a hold rating in a research report on Friday, April 5th. JPMorgan Chase & Co. restated an overweight rating on shares of AstraZeneca in a research report on Thursday, April 11th. Finally, HSBC boosted their price target on shares of AstraZeneca from GBX 5,140 ($67.16) to GBX 5,180 ($67.69) and gave the stock a reduce rating in a research report on Tuesday, April 2nd. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. AstraZeneca has a consensus rating of Hold and an average price target of GBX 6,362.70 ($83.14).
Shares of LON AZN opened at GBX 5,889 ($76.95) on Tuesday. The company has a market capitalization of $77.25 billion and a PE ratio of 34.64. AstraZeneca has a 52-week low of GBX 4,928.50 ($64.40) and a 52-week high of GBX 6,540 ($85.46). The company has a debt-to-equity ratio of 136.31, a quick ratio of 0.71 and a current ratio of 0.96.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: Green Investing
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.